Vaccine candidate Mambisa entered the world list of nasal immunogens in a clinical essay phase, stated Gerardo Guillén Nieto, Biomedical Research Director of the Genetic Engineering and Biotechnology Center (CIGB).

The doctor referred that, among the more than 300 vaccine candidates in the world and of the candidates that has reached a clinical stage, Mambisa, is one of the five that are administrated by airways, according to posted statements on the CIGB profile on social network Twitter.

He pointed out that is it demonstrated that for those who are convalescent from Covid-19, a single dose is enough to stimulate the respond while reaching an antibody level similar or higher than the one in people who has not been in contact with the virus.

Those who get this treatment should have been medically discharged for at least two month after getting the virus, before being treated with the vaccine candidate. They also should be fully compensated from their basis or chronic diseases if this is the case.

The Center for Medicine, Equipment and Medical Devices Control of Cuba approved last July 13 the Phase I/II clinical essay in order to evaluate safety and immunogenicity of vaccine candidate Mabisa- nasal - and Abdala intramuscular vaccine, a study headed on the reinforcement of immunity in Covid-19 convalescents.

The information, published in the Cuban Public Record of Clinical Essays, states that the study will be carried out in Hospital Clinico-Quirurgico “Hermanos Amejeiras with 120 subjects, with four groups in Stage I and two groups in Stage II.

Among the benefits of Mambisa it is stated that its formulation is one of a kind, based in  a recombined form of producing antigens platform, highly safe technology( with slightly reported side effects) and a chance of applying multiple doses under the aim of reinforcing immune respond in time, said Marta Ayala Ávila, General Director of CIGB.

Another advantage highlights its potentiality for inducing this kind of action by nasopharyngeal mucosa which is particularly convenient, on a vaccine candidate against a disease with an entry door by airways.

Soource: CAN

Related info

Soberana 02 reaches a 91.2% efficacy in its three doses scheme. (+video)

Abdala shows 92.28% efficacy in its unique three doses scheme.

Cuba elaborates anti Covid-19 protocol for immunization in pregnant women.